Sickle Cell Disease PKR Activators Competition June 24, 2020 Biotech & Pharma, Clinical Trials by Mellalta Analyst Leave a Comment on Sickle Cell Disease PKR Activators Competition PKR Candidates, FT-4202 & Mitapivat established proof of concept in Phase I trials Read More
Agios’s PKR Activator, Mitapivat’s strategy for Sickle Cell Disease (SCD) June 23, 2020 Biotech & Pharma, Clinical Trials by Mellalta Analyst Leave a Comment on Agios’s PKR Activator, Mitapivat’s strategy for Sickle Cell Disease (SCD) Agios Pharmaceuticals, shared the proof of clinical concept that has been established based on preliminary analysis in the phase 1 study of mitapivat (AG-348) in patients with sickle cell anemia. We, Mellalta Meets would like […] Read More